Literature DB >> 8329786

Physical and chemical compatibility of intravenous ciprofloxacin with other drugs.

L K Jim1.   

Abstract

OBJECTIVE: To determine the physical and chemical compatibilities of ciprofloxacin lactate infusion with other commonly used intravenously administered drugs.
DESIGN: Ciprofloxacin lactate injection in a commercially available concentration of 2 mg/mL was mixed with 15 intravenous drugs during simulated Y-site injection. Ciprofloxacin was mixed with usually employed concentrations of other drugs in a 1:1 ratio and examined physically by visual inspection and chemically by HPLC analysis. Adsorption of ciprofloxacin to intravenous administration sets with or without inline filters was also studied.
SETTING: The study was carried out at ambient temperature (25 degrees C) under fluorescent lighting except for vitamin B complex, which was protected from light. All samples were prepared in a laminar airflow hood. MAIN OUTCOME MEASURES: Physical incompatibility was determined by visual inspection against a black-and-white background, and chemical incompatibility was measured by a stability-indicating HPLC assay for ciprofloxacin. Concentrations determined at time zero (before mixing) were defined as 100 percent. Values estimated for each sample at subsequent time points were calculated as percentages of the initial concentration. Recovery below 90 percent of the initial concentration is defined as significant loss.
RESULTS: Of the 15 drugs studied, only heparin, furosemide, and teicoplanin were found to be incompatible with ciprofloxacin. Adsorption of ciprofloxacin to administration sets with and without inline filters was minimal. Metronidazole was also found to decrease to 90 percent of its initial concentration immediately upon mixing.
CONCLUSIONS: Ciprofloxacin ready-to-infuse solution is compatible with most of the drugs studied except heparin, furosemide, teicoplanin, and, perhaps, metronidazole. Because only the stability and potency of ciprofloxacin were studied, further testing is needed to confirm if any chemical deterioration of the other drugs occurred when combined with ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8329786     DOI: 10.1177/106002809302700604

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  4 in total

Review 1.  Clinical pharmacokinetics of teicoplanin.

Authors:  A P Wilson
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

Review 2.  Considerations in developing a target product profile for parenteral pharmaceutical products.

Authors:  William J Lambert
Journal:  AAPS PharmSciTech       Date:  2010-09-15       Impact factor: 3.246

3.  An in vitro study on the compatibility and precipitation of a combination of ciprofloxacin and vancomycin in human vitreous.

Authors:  M Hui; A K H Kwok; C P Pang; S W Cheung; R C Y Chan; D S C Lam; A F B Cheng
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

Review 4.  Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D H Peters
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.